therapeutic potential in clinical trials. T cells expressing a chimeric antigen receptor (CAR)
are endowed with a new specificity to target tumor-associated antigen (TAA) independent of
major histocompatibility complex. Our approach to nonviral gene transfer in T cells uses ex
vivo numeric expansion of CAR+ T cells on irradiated artificial antigen presenting cells
(aAPC) bearing the targeted TAA. The requirement for aAPC to express a desired TAA limits …